MiNK to Provide Corporate Update and First Quarter 2024 Financial Report
MiNK to Provide Corporate Update and First Quarter 2024 Financial Report
NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its first quarter 2024 financial results before the market opens on Tuesday, May 14, 2024. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and to provide a corporate update.
纽约，2024年4月30日（GLOBE NEWSWIRE）—— MinK Therapeutics, Inc.（纳斯达克股票代码：INKT）是一家临床阶段的生物制药公司，率先发现、开发和商业化治疗癌症和其他免疫介导疾病的异基因、现成不变自然杀伤剂 T（inkT）细胞疗法，今天宣布，该公司将在2024年前发布其2024年第一季度财务业绩市场将于2024年5月14日星期二开盘。MinK高管将在美国东部时间当天上午 8:30 主持电话会议和网络直播，讨论结果并提供公司最新情况。
Conference Call
电话会议
Dial-in numbers: 646-307-1963 (U.S. – NY), (800) 715-9871 (U.S. & Canada)
拨入号码：646-307-1963（美国 — 纽约），（800）715-9871（美国和加拿大）
Conference ID: 7888464
会议 ID：7888464
Webcast
网络直播
A live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company's website at https://investor.minktherapeutics.com/events-and-presentations and via https://edge.media-server.com/mmc/p/vc5onn9q.
电话会议的网络直播和重播可从公司网站的活动和演示页面上观看，网址为 https://investor.minktherapeutics.com/events-and-presentations 并通过 https://edge.media-server.com/mmc/p/vc5onn9q。
About MiNK Therapeutics
关于 MinK Therapeut
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com/ or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels.
MinK Therapeutics是一家处于临床阶段的生物制药公司，开创了用于治疗癌症和其他免疫介导疾病的异基因不变自然杀伤T（InkT）细胞疗法的发现、开发和商业化。MinK正在推进原生和下一代工程InkT程序的管道，其平台旨在促进可扩展和可重复的制造，以实现现成交付。该公司总部位于纽约州纽约。欲了解更多信息，请访问 https://minktherapeutics.com/ 或者 @MiNK_iNKT。可能对投资者很重要的信息将定期发布在我们的网站和社交媒体渠道上。
Investor Contact
投资者联系人
917-362-1370
917-362-1370
Media Contact
媒体联系人
781-674-4428
781-674-4428
Source: MiNK Therapeutics
来源：MinK Therapeutics
译文内容由第三方软件翻译。